Vonapanitase

Phase 3Protein / enzyme

PProteon Therapeutics

Vonapanitase is one of 64 small molecule programs targeting Peripheral Artery Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral Artery DiseaseActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Peripheral Artery DiseasePhase 1

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

Vonapanitase

PProteon Therapeutics

Phase 3

1 4

Lorelco

Sanofi

Preclinical

1 5

Glucotrol

Pfizer

Preclinical

1 6

Vemlidy

Gilead

Preclinical

1 7

Activase

Flomax

Genotropin

1 10

Januvia

ZZydus Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Peripheral Artery Disease2 trials

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

Withdrawn·PProteon Therapeutics·Phase 1·NCT02953496

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

Completed·PProteon Therapeutics·Phase 1·NCT02956993·29 enrolled

Chronic Kidney Disease1 trial

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

Completed·PProteon Therapeutics·Phase 3·NCT02414841·696 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Vonapanitase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vonapanitase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vonapanitase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Proteon Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: PProteon Therapeutics

Vonapanitase

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Peripheral Artery Disease2 trials

Chronic Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News